KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Net Margin (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Net Margin data on record, last reported at 90.43% in Q4 2025.

  • For Q4 2025, Net Margin fell 9647.0% year-over-year to 90.43%; the TTM value through Dec 2025 reached 341.47%, down 14029.0%, while the annual FY2025 figure was 341.47%, 14029.0% down from the prior year.
  • Net Margin reached 90.43% in Q4 2025 per PACB's latest filing, up from 98.85% in the prior quarter.
  • Across five years, Net Margin topped out at 47.42% in Q3 2021 and bottomed at 1146.81% in Q1 2025.
  • Average Net Margin over 5 years is 214.97%, with a median of 149.36% recorded in 2023.
  • The widest YoY moves for Net Margin: up 37583bps in 2025, down -94537bps in 2025.
  • A 5-year view of Net Margin shows it stood at 192.48% in 2021, then tumbled by -60bps to 308.5% in 2022, then skyrocketed by 54bps to 140.55% in 2023, then surged by 104bps to 6.04% in 2024, then crashed by -1596bps to 90.43% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 90.43% in Q4 2025, 98.85% in Q3 2025, and 105.44% in Q2 2025.